Trials / Withdrawn
WithdrawnNCT02955368
Clinical Trial to Evaluate the Efficacy and Safety of DP-R212
A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R212 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Alvogen Korea · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine superiority of DP-R212 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DP-R212 | DP-R212 + C1-R212 placebo + C2-R212 placebo |
| DRUG | C1-R212 | DP-R212 placebo + C1-R212 + C2-R212 placebo |
| DRUG | C2-R212 | DP-R212 placebo + C1-R212 placebo + C2-R212 |
Timeline
- Start date
- 2017-02-01
- Primary completion
- 2017-07-01
- Completion
- 2017-08-01
- First posted
- 2016-11-04
- Last updated
- 2017-06-05
Source: ClinicalTrials.gov record NCT02955368. Inclusion in this directory is not an endorsement.